{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I"}],"populationDescription":"Participants did not complete follow-up per protocol as trial was terminated early","reportingStatus":"POSTED","timeFrame":"5 yrs following treatment","title":"Patterns of Failure","type":"SECONDARY"}